《大行報告》中金:上海醫藥(02607.HK)首三季收入略超預期 利潤符合預期
中金發表評級報告指,上海醫藥(02607.HK)首三季收入1,746.12億元人民幣,按年增8.5%,淨利潤48.14億元人民幣,按年增7.4%,單計第三季收入629.04億元,按年增12.9%,淨利潤11.18億元,按年增22%,中金表示,首三季收入略超於該行預料,利潤則符合預期,主要由於疫情的負面影響已逐漸減輕。
中金表示,公司加大中藥佈局,積極開展大品種研發和推廣工作,故認為公司積極拓展工業新品類,未來3至5年相關業務和利潤貢獻有望上升;截至今年10月27日,公司新增進口總代產品數量共計23個,故中金認為公司有望繼續保持進口總代理的領先地位。
中金表示,將公司今年及明年的盈利預測不變,並將其H股目標價下調4.7%至15.34元,維持其評級為「跑贏行業」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.